Suppr超能文献

临床规模下人 T 淋巴细胞培养的生物工艺开发。

Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale.

机构信息

Research Center Juelich GmbH, Institute of Biotechnology 2, 52428, Juelich, Germany.

出版信息

Cytotechnology. 2002 Jan;38(1-3):135-45. doi: 10.1023/A:1021174619613.

Abstract

Adoptive transfer of large numbers of donor-derived T-lymphocytesmay offer a promising treatment of a variety of viral and malignant diseases. The key step in this approach is the ex vivo generation of sufficient quantities of these cells in a short time.We have investigated the influence of several important cultivation parameters on the proliferation of human T-lymphocytes to develop a large-scale fermentation process usingdifferent types of stirred bioreactors. Such systems offer manypotential advantages over the static culture systems commonlyused today.Peripheral blood mononuclear cells of healthy but CMV positive donors were stimulated with monoclonal antibodies (anti-CD3 and anti-CD28) and Interleukin-2. The influence of osmolality, Interleukin-2 concentration, pH, oxygen tension, feeding strategyand temperature on T-cell proliferation was investigated and theoptimised conditions were transferred to a novel stirred suspension bioreactor with an especially designed magnetic stirrbar to minimize the shear force (working volume 550 ml) and a standard stirred vessel (working volume 1000 ml).Preferable conditions for the cultivation of primary T-lymphocytes were an osmolality of 276-330 mOsmol kg(-1),an Interleukin-2 concentration of 100 U ml(-1), a pH rangeof 7.0 to 7.3, an oxygen tension of 5-50% and a temperature of 38.5 degrees C. After 238 h of cultivation 2.8 x 10(9) cells in the stirred vesseland 1.5 x 10(9) cells in the suspension bioreactor were obtained with a percentage of T-cells >94%. The specificity of the cells wasmaintained during cultivation as proven by IFN-gamma secretionafter exposure to a hCMV protein.

摘要

采用大量供体来源的 T 淋巴细胞进行过继转移可能为多种病毒和恶性疾病提供一种很有前途的治疗方法。该方法的关键步骤是在短时间内体外生成足够数量的这些细胞。我们研究了几种重要的培养参数对人 T 淋巴细胞增殖的影响,以开发使用不同类型搅拌式生物反应器的大规模发酵工艺。与当今常用的静态培养系统相比,这些系统具有许多潜在的优势。用单克隆抗体(抗-CD3 和抗-CD28)和白细胞介素-2 刺激健康但 CMV 阳性供体的外周血单个核细胞。研究了渗透压、白细胞介素-2 浓度、pH 值、氧分压、进料策略和温度对 T 细胞增殖的影响,并将优化条件转移到一种新型搅拌悬浮生物反应器中,该生物反应器具有专门设计的磁性搅拌棒,可将剪切力降至最低(工作体积为 550 ml),并采用标准搅拌釜(工作体积为 1000 ml)。原代 T 淋巴细胞培养的最佳条件为渗透压 276-330 mOsmol kg(-1)、白细胞介素-2 浓度 100 U ml(-1)、pH 值 7.0-7.3、氧分压 5-50%和 38.5 摄氏度。培养 238 小时后,搅拌釜中可获得 2.8 x 10(9)个细胞,悬浮式生物反应器中可获得 1.5 x 10(9)个细胞,T 细胞百分比>94%。如 IFN-γ分泌所示,细胞在培养过程中的特异性得以维持γ 在暴露于 hCMV 蛋白后。

相似文献

1
Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale.
Cytotechnology. 2002 Jan;38(1-3):135-45. doi: 10.1023/A:1021174619613.
2
Bioprocess development for mass production of size-controlled human pluripotent stem cell aggregates in stirred suspension bioreactor.
Tissue Eng Part C Methods. 2012 Nov;18(11):831-51. doi: 10.1089/ten.TEC.2012.0161. Epub 2012 Jun 13.
3
New milliliter-scale stirred tank bioreactors for the cultivation of mycelium forming microorganisms.
Biotechnol Bioeng. 2010 Jun 15;106(3):443-51. doi: 10.1002/bit.22706.
4
Bioreactor scale-up and oxygen transfer rate in microbial processes: an overview.
Biotechnol Adv. 2009 Mar-Apr;27(2):153-76. doi: 10.1016/j.biotechadv.2008.10.006. Epub 2008 Nov 12.
5
Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture.
Biotechnol Bioeng. 2004 Jan 20;85(2):138-46. doi: 10.1002/bit.10801.
6
Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: shear, proliferation, and the IL-2 receptor.
Biotechnol Bioeng. 2000 May 5;68(3):328-38. doi: 10.1002/(sici)1097-0290(20000505)68:3<328::aid-bit11>3.0.co;2-v.
7
Large-scale cultivation of promastigotes in stirred bioreactor.
J Vector Borne Dis. 2019 Oct-Dec;56(4):345-350. doi: 10.4103/0972-9062.302038.
8
Establishing the scalable manufacture of primary human T-cells in an automated stirred-tank bioreactor.
Biotechnol Bioeng. 2019 Oct;116(10):2488-2502. doi: 10.1002/bit.27088. Epub 2019 Jul 9.
9
Large-scale expansion of human skin-derived precursor cells (hSKPs) in stirred suspension bioreactors.
Biotechnol Bioeng. 2016 Dec;113(12):2725-2738. doi: 10.1002/bit.26040. Epub 2016 Jul 11.

引用本文的文献

1
Piloting a scale-up platform for high-quality human T-cells production.
Front Cell Dev Biol. 2024 Jul 12;12:1427171. doi: 10.3389/fcell.2024.1427171. eCollection 2024.
2
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics.
J Transl Med. 2024 Apr 24;22(1):384. doi: 10.1186/s12967-024-05197-5.
3
Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies.
Bioengineering (Basel). 2022 Dec 15;9(12):808. doi: 10.3390/bioengineering9120808.
4
Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.
J Biol Eng. 2021 Apr 13;15(1):13. doi: 10.1186/s13036-021-00264-7.
6
Optimization manufacture of virus- and tumor-specific T cells.
Stem Cells Int. 2011;2011:434392. doi: 10.4061/2011/434392. Epub 2011 Sep 11.

本文引用的文献

2
Cultivation of hematopoietic stem and progenitor cells: biochemical engineering aspects.
Adv Biochem Eng Biotechnol. 2002;74:111-28. doi: 10.1007/3-540-45736-4_6.
4
6
Immunology and immunotherapy of human cancer: present concepts and clinical developments.
Crit Rev Oncol Hematol. 2000 Apr;34(1):1-25. doi: 10.1016/s1040-8428(99)00059-1.
7
Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: shear, proliferation, and the IL-2 receptor.
Biotechnol Bioeng. 2000 May 5;68(3):328-38. doi: 10.1002/(sici)1097-0290(20000505)68:3<328::aid-bit11>3.0.co;2-v.
8
The use of Teflon cell culture bags to expand functionally active CD8+ cytotoxic T lymphocytes.
J Immunol Methods. 1999 Jul 30;227(1-2):53-63. doi: 10.1016/s0022-1759(99)00068-x.
10
Adoptive immunotherapy.
Cancer Chemother Biol Response Modif. 1997;17:316-27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验